The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

University of Pittsburgh Cancer Institute gets NCI preclinical research contract

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

THE UNIVERSITY OF PITTSBURGH CANCER INSTITUTE, partnered with UPMC CancerCancer, received a contract from NCI to perform preclinical research for the development of new cancer drugs. This commitment could bring up to $10 million in research projects to UPCI over the next five years.

Julie Eiseman, professor of pharmacology and chemical biology, and Jan Beumer, associate professor of pharmaceutical sciences and medicine, will serve as co-principal investigators on the research contract. They also hold a previous NCI preclinical contract, which will conclude next year. The researchers do not yet know specifically what potential drugs they’ll be investigating or in which indications.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account